We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Hippo aims to be the dedicated transportation service for non-emergency and impaired medical victims. With private care homes as customers and an NHS deal secured, they intend to allow quicker hospital bed rotation, free ambulances to attend more emergencies and decreased A&E waiting times. It is currently operating in South East Essex, having an association with South Essex Care & Health Association, and have an NHS deal in place as well. For the future, Hippo aims to develop a specialised management and booking solution that will combine its video camera system, so that patients can be monitored during the journey by the NHS and family members.
days to go: Expired investment: £175,390
Veluba is a zero-emission transport solution for London. It is an application-hailed and pedal-powered eco-cab service for Central London which aims to provide a faster and cheaper solution for its over-polluted and over-congested capital city. The company has 30 Veluba cabs ready to go with and have just launched their app. The vehicles are designed and driven with safety at the forefront and drivers are fully insured. Each Veluba® is provided with digital signage screens, giving prominent ad space, and the possibility for an additional revenue stream. Veluba aims to expand beyond the first depot to reach more of London and become a key part of the city’s growing eco-transport infrastructure. The investment will enable the company to employ additional drivers.

Pitch Rated

76%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £78,590
Q Doctor aims at changing the NHS care delivery with the help of video consulting to benefit patients and clinicians. The company is focusing on delivering a model that keeps modernised NHS care free of charge for the patients. The video solution plugs NHS clinicians to the existing NHS infrastructure and allows them to connect to the NHS patients digitally. With the proceeds, Q Doctor will fulfil its strategy for 2020. It will deploy the funds into labour, development, operations, marketing, and contingency funds.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,386,200
Widewalls is an online platform where art lovers discover and collect modern and contemporary art. In a nutshell, this platform connects art collectors and art dealers. Widewalls presents 3000 art venues, 12,000 artist profiles, and 19,000 articles covering modern and Contemporary art. This platform displays 20,000 artworks to discover and auctions results covering approximately 80% of the market over the past 4 years. In total, more than 120,000 pages on Widewalls are indexed by Google. It is the media partner of 48 international art fairs. The company's mission is to help traditional galleries and auction houses access and serve the online market more efficiently.
days to go: Expired investment: £235,490
ArtAttack is a social network for art e-commerce. They see themselves as a Instagram like app with the addition of a buy button, so it's as much an art sharing platform as it is an art selling platform. 
days to go: Expired investment: £48,430
A new form of electric transport in the bike industry with the use of an affordable and simple conversion kit. Swytch have developed a kinetically rechargeable add-on for existing bikes to convert them into eBikes for a range of up to 50 miles. Funding will result in additional units being manufactured and sold at a 70% margin. The products are available online and currently via 20 independent bike dealers, with over 100 more waiting on stock.
days to go: Expired investment: £349,356
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph